Tolvaptan add‐on therapy in patients with acute heart failure: A systematic review and meta‐analysis

• Main Authors: Xiandu Luo (Author), Qi Jin (Author), Yanqing Wu (Author)
• Format: Book
• Published: Wiley, 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2052-1707; 10.1002/prp2.614
• Keywords: acute heart failure; meta‐analysis; tolvaptan; traditional diuretics; Therapeutics. Pharmacology; RM1-950
• Source: Pharmacology Research & Perspectives, Vol 8, Iss 3, Pp n/a-n/a (2020)

Abstract This study aimed to investigate the short‐term efficacy and safety of tolvaptan as an add‐on to traditional diuretics in patients with acute heart failure (AHF). The PubMed, EMBASE, Cochrane Library, and Web of Science databases were comprehensively searched for all randomized controlled trials (RCTs) that examined AHF patients treated with tolvaptan as a combination therapy with traditional diuretics published on or before December 2, 2019. Efficacy indicators such as improved dyspnea, reduced edema, and changes in urine output and body weight were evaluated. In‐hospital mortality and worsening renal function (WRF) were measured as safety indicators. Data from the published literature included in this study were independently extracted by two reviewers. The Cochrane risk of bias tool was used to evaluate the quality of the included RCTs. Twelve RCTs involving 5577 patients admitted for AHF were included. Compared with traditional diuretics alone, add‐on tolvaptan significantly relieved dyspnea, reduced weight, increased total urine volume and changes in urine volume from baseline, reduced edema, and increased serum sodium concentration in the short term without increasing the mortality. Most importantly, a low dose of tolvaptan (7.5‐15 mg/d) significantly reduced the incidence of WRF, while a high dose (30 mg/d) had the opposite effect. Short‐term add‐on tolvaptan in hospitalized AHF patients could significantly relieve shortness of breath, reduce body weight, improve edema, and increase urine output and serum sodium concentrations without increasing mortality. The protective effects of add‐on tolvaptan against WRF, however, were observed at low doses, but not at high doses.